دورية أكاديمية
أعرض في EDS

Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A secondary CIBMTR analysis.

التفاصيل البيبلوغرافية
العنوان: Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A secondary CIBMTR analysis.
المؤلفون: Schoettler ML; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Westbrook A; Pediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, Georgia, USA., Watkins B; Children's Hospital, New Orleans, Tulane Pediatric Hematology/Oncology, New Orleans, Louisiana, USA., Stenger E; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Qayed M; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Chonat S; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA., Williams KM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
المصدر: British journal of haematology [Br J Haematol] 2024 Jul; Vol. 205 (1), pp. 243-255. Date of Electronic Publication: 2024 May 30.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*/prevention & control , Graft vs Host Disease*/etiology , Thrombotic Microangiopathies*/etiology , Thrombotic Microangiopathies*/epidemiology , Thrombotic Microangiopathies*/prevention & control, Humans ; Female ; Male ; Child ; Adolescent ; Adult ; Child, Preschool ; Middle Aged ; Age Factors ; Young Adult ; Risk Factors ; Time Factors ; Infant ; Incidence
مستخلص: Most reports of risk factors (RF) for developing transplant-associated thrombotic microangiopathy (TA-TMA) and death are derived from paediatric and young adult cohorts, with minimal data on differences in RF and outcomes by age. In this secondary CIBMTR analysis, we used a previously prepared dataset that included all first allogenic haematopoietic cell transplantation (HCT) recipients with malignant or non-malignant diseases between 2008 and 2016. The incidence of TA-TMA 6 months post HCT was similar in children and adults 2.1% and 2.0% respectively. Grade 2-4 acute graft-versus-host disease (aGVHD) was a significant adjusted RF for developing TA-TMA in both children and adults. In adults, additional adjusted RFs for TA-TMA included female sex and black race, and in children an unrelated donor. Compared to a calcineurin inhibitor and sirolimus, other forms of GVHD prophylaxis had an adjusted decreased risk of developing TA-TMA in adults. Adjusted RF for death in those with TA-TMA (n = 652) included age ≥18 years old, early onset of TA-TMA diagnosis (<100 days post HCT), grade 3-4 aGVHD and a performance score of <90 prior to HCT. In this cohort, the incidence of TA-TMA was similar in children and adults, and TA-TMA timing was a newly identified RF for death.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
References: Mizuno K, Dandoy C, Teusink‐Cross A, Davies S, Vinks A, Jodele S. Eculizumab PK/PD modeling and simulation for personalized dose adjustment in bleeding patients with stem cell transplant‐associated thrombotic microangiopathy (TA‐TMA). Clin Pharmacol Ther. 2022;111(Suppl 1):S37. https://doi.org/10.1002/cpt.2521.
Moiseev IS, Tsvetkova TG, Ruutu T. Practical review of current approaches to diagnosis and treatment of transplant‐associated thrombotic microangiopathy. Cell Ther Transplant. 2021;10(2):17–25. https://doi.org/10.18620/CTT‐1866‐8836‐2021‐10‐2‐17‐25.
Schoettler ML, Bhatt H, Vasu S. A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant‐associated thrombotic microangiopathy. Front Immunol. 2023;13:1064203. https://doi.org/10.3389/fimmu.2022.1064203.
Dvorak CC, Higham C, Shimano KA. Transplant‐associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr. 2019;7:133. https://doi.org/10.3389/fped.2019.00133.
Jodele S, Sabulski A. Reeling in complement in transplant‐associated thrombotic microangiopathy: You're going to need a bigger boat. Am J Hematol. 2023;98(S4):S57–S73. https://doi.org/10.1002/ajh.26872.
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy. Blood. 2015;127(8):989–997. https://doi.org/10.1182/blood‐2015‐08‐663435.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant‐associated thrombotic microangiopathy. Blood. 2013;122(12):2003–2007. https://doi.org/10.1182/blood‐2013‐05‐501445.
Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, et al. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 2020;4(13):3169–3179. https://doi.org/10.1182/bloodadvances.2020002007.
Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, et al. Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020;95(10):1170–1179. https://doi.org/10.1002/ajh.25922.
Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, et al. Transplant‐associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant. 2019;25(3):570–576. https://doi.org/10.1016/j.bbmt.2018.10.015.
Schoettler ML, French K, Harris A, Bryson E, Deeb L, Hudson Z, et al. D‐dimer and sinusoidal obstructive syndrome‐novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study. Am J Hematol. 2024;99:370–379. https://doi.org/10.1002/ajh.27186.
Schoettler M, Lehmann LE, Margossian S, Lee M, Kean LS, Kao PC, et al. Risk factors for transplant‐associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020;4(11):2536–2547. https://doi.org/10.1182/bloodadvances.2019001242.
Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, et al. Transplantation‐associated thrombotic microangiopathy risk stratification: is there a window of opportunity to improve outcomes? Transplant Cell Ther. 2022;28(7):392.e1–392.e9. https://doi.org/10.1016/j.jtct.2022.04.019.
Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, et al. Transplant‐associated thrombotic microangiopathy in pediatric patients: pre‐HSCT risk stratification and prophylaxis. Blood Adv. 2021;5(8):2106–2114. https://doi.org/10.1182/bloodadvances.2020003988.
Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, et al. A pragmatic multi‐institutional approach to understanding transplant‐associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2020;5(1):1–11. https://doi.org/10.1182/bloodadvances.2020003455.
Zhao P, Wu Y, He Y, Chong S, Qu QY, Deng RX, et al. A prognostic model (BATAP) with external validation for patients with transplant‐associated thrombotic microangiopathy. Blood Adv. 2021;5(24):5479–5489. https://doi.org/10.1182/bloodadvances.2021004530.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT‐associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–653.
Vasu S, Bostic M, Zhao Q, Sharma N, Puto M, Knight S, et al. Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant‐associated thrombotic microangiopathy in adults. Blood Adv. 2022;6(4):1342–1349. https://doi.org/10.1182/bloodadvances.2021004933.
Sridharan M, Go RS, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Incidence and mortality outcomes in allogeneic transplant‐associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2018;24(3):S329–S330. https://doi.org/10.1016/j.bbmt.2017.12.387.
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, risk factors for and outcomes of transplant‐associated thrombotic microangiopathy. Br J Haematol. 2020;189(6):1171–1181. https://doi.org/10.1111/bjh.16457.
Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol. 2009;4(2):345–353. https://doi.org/10.2215/CJN.02070508.
Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, et al. Complement‐mediated thrombotic microangiopathy as a link between endothelial damage and steroid‐refractory GVHD. Blood Adv. 2018;2(20):2619–2628. https://doi.org/10.1182/bloodadvances.2018020321.
Gavriilaki E, Chrysanthopoulou A, Sakellari I, Batsis I, Mallouri D, Touloumenidou T, et al. Linking complement activation, coagulation, and neutrophils in transplant‐associated thrombotic microangiopathy. Thromb Haemost. 2019;119(9):1433–1440. https://doi.org/10.1055/s‐0039‐1692721.
Gavriilaki E, Touloumenidou T, Sakellari I, Batsis I, Mallouri D, Psomopoulos F, et al. Pretransplant genetic susceptibility: clinical relevance in transplant‐associated thrombotic microangiopathy. Thromb Haemost. 2020;120(4):638–646. https://doi.org/10.1055/s‐0040‐1702225.
Schoettler M, Stenger EO, Spencer K, Lutterman D, Rumbika S, Jones J, et al. Sickle cell disease is a risk factor for transplant‐associated thrombotic microangiopathy in children. Blood Adv. 2022;7:1784–1795. https://doi.org/10.1182/bloodadvances.2022008058.
Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, et al. Transplant‐associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007;13(4):469–477. https://doi.org/10.1016/j.bbmt.2006.11.020.
Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(5):638–644. https://doi.org/10.1097/01.tp.0000230373.82376.46.
Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant‐associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52:1399–1405. https://doi.org/10.1038/bmt.2017.119.
Faraci M, Bertaina A, Luksch R, et al. Sinusoidal obstruction syndrome/Veno‐occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian hematology‐oncology association‐hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):313–320. https://doi.org/10.1016/j.bbmt.2018.09.027.
Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):551–557. https://doi.org/10.1016/j.bbmt.2005.04.007.
Labrador J, López‐Corral L, López‐Godino O, Vázquez L, Cabrero‐Calvo M, Pérez‐López R, et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant. 2014;49(5):684–690. https://doi.org/10.1038/bmt.2014.17.
Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation‐associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2023;29:163. https://doi.org/10.1016/j.jtct.2022.11.015.
معلومات مُعتمدة: K12CA237806 Center for Strategic Scientific Initiatives, National Cancer Institute; ASH Foundation, Robert Wood Johnson Foundation
فهرسة مساهمة: Keywords: adult; haematopoietic cell transplantation (HCT); paediatric; risk factors; transplant‐associated thrombotic microangiopathy (TA‐TMA)
تواريخ الأحداث: Date Created: 20240531 Date Completed: 20240712 Latest Revision: 20240712
رمز التحديث: 20240712
DOI: 10.1111/bjh.19506
PMID: 38817006
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2141
DOI:10.1111/bjh.19506